Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Menter

Showing results (221-230 of 298) with videos related to

Pageof 30
Sort By:
Journal of the American Academy of Dermatology|January 19, 2016
Translating psoriasis guidelines into practice: Important gaps revealedReva Bhushan, Mark G Lebwohl, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
The Journal of Dermatological Treatment|January 16, 2016
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasisRobert Bissonnette, Monica Luchi, Rosanne Fidelus-Gort, et al.
The Journal of Investigative Dermatology|March 19, 2022
Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLARJunko Takeshita, Matthias Augustin, Elke M G J de Jong, et al.
The Journal of Investigative Dermatology|November 11, 2011
A subset of methylated CpG sites differentiate psoriatic from normal skinElisha D O Roberson, Ying Liu, Caitriona Ryan, et al.
Human Genetics|December 17, 2002
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibilityRebecca A Speckman, Jil A Wright Daw, Cynthia Helms, et al.
Journal of the American Academy of Dermatology|November 14, 2006
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisAlan Menter, Steven R Feldman, Gerald D Weinstein, et al.
Journal of the American Academy of Dermatology|October 7, 2008
Psoriasis: improving adherence to topical therapySteven R Feldman, Elizabeth J Horn, Rajesh Balkrishnan, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomesLeon Kircik, Jerry Bagel, Neil Korman, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
Pageof 30

Showing results (221-230 of 298) with videos related to

Sort By:
Pageof 30
Journal of the American Academy of Dermatology|January 19, 2016
Translating psoriasis guidelines into practice: Important gaps revealedReva Bhushan, Mark G Lebwohl, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 22, 2020
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
The Journal of Dermatological Treatment|January 16, 2016
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasisRobert Bissonnette, Monica Luchi, Rosanne Fidelus-Gort, et al.
The Journal of Investigative Dermatology|March 19, 2022
Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLARJunko Takeshita, Matthias Augustin, Elke M G J de Jong, et al.
The Journal of Investigative Dermatology|November 11, 2011
A subset of methylated CpG sites differentiate psoriatic from normal skinElisha D O Roberson, Ying Liu, Caitriona Ryan, et al.
Human Genetics|December 17, 2002
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibilityRebecca A Speckman, Jil A Wright Daw, Cynthia Helms, et al.
Journal of the American Academy of Dermatology|November 14, 2006
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisAlan Menter, Steven R Feldman, Gerald D Weinstein, et al.
Journal of the American Academy of Dermatology|October 7, 2008
Psoriasis: improving adherence to topical therapySteven R Feldman, Elizabeth J Horn, Rajesh Balkrishnan, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomesLeon Kircik, Jerry Bagel, Neil Korman, et al.
The Journal of Dermatological Treatment|December 7, 2007
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisDennis A Revicki, Mary Kaye Willian, Alan Menter, et al.
Pageof 30